Singapore markets closed
Straits Times Index
3,253.79 -3.03 (-0.09%) S&P 500
4,297.14 +16.99 (+0.40%) Dow
33,912.44 +151.39 (+0.45%) Nasdaq
13,128.05 +80.87 (+0.62%) BTC-USD
24,083.25 -128.25 (-0.53%) CMC Crypto 200
573.66 -17.10 (-2.89%)
PFE Jun 2023 45.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 02:34PM EDT. Market open.
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 45.00 |
| Expiry date | 2023-06-16 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.57k |
- Editor's pickYahoo Finance Video
UK approves COVID vaccine that targets Omicron subvariants
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
- Motley Fool
1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
On that note, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) worked together to develop and commercialize their coronavirus vaccine, Comirnaty. In BioNTech's second quarter, practically 100% of its product sales, totaling around $3.3 billion, were attributable to its share of jab revenue.
- Zacks
Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
© 2022 Yahoo. All rights reserved.
